Published in Mol Ther on September 15, 2009
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Characterization of species C human adenovirus serotype 6 (Ad6). Virology (2011) 1.59
Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer. PLoS One (2015) 1.43
Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther (2011) 1.42
Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses (2010) 1.30
Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood (2010) 1.25
Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses (2010) 1.17
The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget (2011) 1.10
Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther (2010) 1.02
Targeting adenoviruses with factor x-single-chain antibody fusion proteins. Hum Gene Ther (2010) 0.95
Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors. J Virol (2011) 0.84
Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening. Cancer Res (2010) 0.82
FX and host defense evasion tactics by adenovirus. Mol Ther (2013) 0.80
Imaging luciferase-expressing viruses. Methods Mol Biol (2012) 0.79
Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5. Biomedicines (2017) 0.77
Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers. Mol Ther Oncolytics (2016) 0.76
Effect of adenoviral delivery of prodynorphin gene on experimental inflammatory pain induced by formalin in rats. Int J Clin Exp Med (2014) 0.75
Oncolytic virotherapy: the questions and the promise. Oncolytic Virother (2013) 0.75
Targeting Melanoma with Cancer-Killing Viruses. Open Virol J (2017) 0.75
Adenovirus serotype 5 hexon mediates liver gene transfer. Cell (2008) 5.00
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol (2005) 3.19
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol (2008) 3.01
Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A (2008) 3.00
Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood (2006) 2.67
Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther (1997) 2.62
The innate immune response to adenovirus vectors. Hum Gene Ther (2004) 2.35
The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol (1996) 2.25
The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther (2008) 2.21
China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst (2006) 2.20
Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther (2001) 2.19
Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther (2007) 1.94
Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol (2008) 1.93
Infection of mouse liver by human adenovirus type 5. J Gen Virol (1978) 1.74
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74
Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther (2002) 1.69
Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther (2008) 1.66
Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res (2007) 1.64
Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res (2008) 1.57
Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther (2005) 1.52
Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther (2002) 1.49
Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol (1999) 1.49
Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol (2000) 1.43
Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A (2008) 1.38
The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther (2003) 1.37
Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther (2003) 1.35
Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology (2003) 1.35
Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res (2007) 1.31
Repopulation of murine Kupffer cells after intravenous administration of liposome-encapsulated dichloromethylene diphosphonate. Am J Pathol (1996) 1.28
Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver. Mol Ther (2009) 1.23
A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther (2003) 1.22
Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther (2009) 1.21
Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res (2007) 1.20
Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther (2006) 1.16
Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination. Hum Gene Ther (2004) 1.15
Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol (2008) 1.14
Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther (2005) 1.13
Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther (2009) 1.13
Transcriptional repression of interleukin-6 gene by adenoviral E1A proteins. J Biol Chem (1992) 1.06
Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. Clin Cancer Res (2001) 1.00
Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol (2001) 0.99
Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther (2007) 0.99
Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther (2005) 0.98
A demand for next-generation oncolytic adenoviruses. Curr Opin Mol Ther (2006) 0.96
Induction and inhibition of innate inflammatory responses by adenovirus early region proteins. Viral Immunol (2005) 0.92
Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy. Cancer Res (2003) 0.88
An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy. Int J Oncol (2007) 0.84
Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt (2007) 3.04
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol (2008) 3.01
Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther (2007) 1.94
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther (2005) 1.86
Protection of the coronary arteries during epicardial radiofrequency ablation with intracoronary chilled saline irrigation: assessment in an in vitro model. J Cardiovasc Electrophysiol (2006) 1.70
Characterization of species C human adenovirus serotype 6 (Ad6). Virology (2011) 1.59
Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol (2003) 1.58
A multitasking oncolytic adenovirus vector. Mol Ther (2003) 1.57
Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res (2008) 1.57
Lentiviral vectors: basic to translational. Biochem J (2012) 1.49
Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther (2011) 1.42
Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol Med (2007) 1.36
Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. Mol Ther (2003) 1.33
Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther (2008) 1.28
Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One (2009) 1.26
Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol Ther (2004) 1.26
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology (2009) 1.23
Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther (2005) 1.22
Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther (2009) 1.21
Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. J Virol (2009) 1.18
Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther (2006) 1.16
Bipolar ablation of the interventricular septum is more efficient at creating a transmural line than sequential unipolar ablation. Pacing Clin Electrophysiol (2010) 1.15
Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination. Hum Gene Ther (2004) 1.15
Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahari. J Virol (2010) 1.13
An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling. Cancer Res (2004) 1.12
Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology (2006) 1.11
Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. J Virol (2011) 1.09
Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX. J Virol (2006) 1.09
Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther (2007) 1.08
Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine (2007) 1.08
A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proc Natl Acad Sci U S A (2004) 1.08
Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum Gene Ther (2008) 1.01
Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses (2009) 1.01
In vivo evaluation of gene therapy vectors in ex vivo-derived marrow stromal cells for bone regeneration in a rat critical-size calvarial defect model. Hum Gene Ther (2003) 1.01
Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther (2010) 0.98
In vitro release of plasmid DNA from oligo(poly(ethylene glycol) fumarate) hydrogels. J Control Release (2005) 0.97
The role of T cell antagonism and original antigenic sin in genetic immunization. J Immunol (2002) 0.96
Evaluation of bone regeneration by DNA release from composites of oligo(poly(ethylene glycol) fumarate) and cationized gelatin microspheres in a critical-sized calvarial defect. J Biomed Mater Res A (2006) 0.95
Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther (2011) 0.95
Characterization of DNA release from composites of oligo(poly(ethylene glycol) fumarate) and cationized gelatin microspheres in vitro. J Biomed Mater Res A (2006) 0.95
Targeting adenoviruses with factor x-single-chain antibody fusion proteins. Hum Gene Ther (2010) 0.95
Adeno-associated virus serotype 8 gene transfer rescues a neonatal lethal murine model of propionic acidemia. Hum Gene Ther (2011) 0.93
The transcription factor IRF3 triggers "defensive suicide" necrosis in response to viral and bacterial pathogens. Cell Rep (2013) 0.93
Synthesis and conformational evaluation of a novel gene delivery vector for human mesenchymal stem cells. Biomacromolecules (2008) 0.92
Deoxyribonuclease II is a lysosomal barrier to transfection. Mol Ther (2003) 0.91
Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy. Dis Model Mech (2013) 0.91
Maximizing antigen targeting to the proteasome for gene-based vaccines. Mol Ther (2004) 0.90
A library-selected, Langerhans cell-targeting peptide enhances an immune response. DNA Cell Biol (2004) 0.90
Circulating antibodies and macrophages as modulators of adenovirus pharmacology. J Virol (2013) 0.90
Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting. J Virol (2005) 0.89
Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy. Hum Gene Ther (2009) 0.88
Intramyocardial adiposity after myocardial infarction: new implications of a substrate for ventricular tachycardia. Circulation (2013) 0.88
Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2. J Virol (2004) 0.88
Comparison of electroanatomic contact and noncontact mapping of ventricular scar in a postinfarct ovine model with intramural needle electrode recording and histological validation. Circ Arrhythm Electrophysiol (2008) 0.87
Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS One (2011) 0.87
Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther (2003) 0.86
Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res (2011) 0.86
Selection of chronic lymphocytic leukemia binding peptides. Cancer Res (2003) 0.85
Identification of a new human adenovirus protein encoded by a novel late l-strand transcription unit. J Virol (2007) 0.84
Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors. Cancer Gene Ther (2005) 0.83
Heme oxygenase-1 regulates the immune response to influenza virus infection and vaccination in aged mice. FASEB J (2012) 0.83
Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PLoS One (2013) 0.83
Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Ther (2002) 0.83
Development and characterization of enhanced green fluorescent protein and luciferase expressing cell line for non-destructive evaluation of tissue engineering constructs. Biomaterials (2004) 0.83
Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing. Mol Ther (2013) 0.82
Adenovirus immunoregulatory E3 proteins prolong transplants of human cells in immunocompetent mice. Virus Res (2005) 0.82
Construction and characterization of E1-minus replication-defective adenovirus vectors that express E3 proteins from the E1 region. Virology (2002) 0.82
Increased transduction of skeletal muscle cells by fibroblast growth factor-modified adenoviral vectors. Hum Gene Ther (2006) 0.81
A vector-host system to fingerprint virus tropism. Hum Gene Ther (2012) 0.81
Low seroprevalent species D adenovirus vectors as influenza vaccines. PLoS One (2013) 0.81
Real-time dynamic imaging of virus distribution in vivo. PLoS One (2011) 0.81
Generation of genome-wide CD8 T cell responses in HLA-A*0201 transgenic mice by an HIV-1 ubiquitin expression library immunization vaccine. J Immunol (2002) 0.80
Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines. J Immunol (2004) 0.80
Improved transduction of human corneal epithelial progenitor cells with cell-targeting adenoviral vectors. Exp Eye Res (2006) 0.79
Coagulation factor binding orientation and dimerization may influence infectivity of adenovirus-coagulation factor complexes. J Virol (2013) 0.79
Clinical evaluation of a new technique to monitor return electrode skin temperature during radiofrequency ablation. J Interv Card Electrophysiol (2012) 0.79
Rad23 as a reciprocal agent for stimulating or repressing immune responses. Hum Gene Ther (2005) 0.78
Beta cell regeneration after single-round immunological destruction in a mouse model. Diabetologia (2014) 0.78
Long-term sex-biased correction of circulating propionic acidemia disease markers by adeno-associated virus vectors. Hum Gene Ther (2015) 0.77
Effects of adeno-associated virus serotype and tissue-specific expression on circulating biomarkers of propionic acidemia. Hum Gene Ther (2014) 0.77
CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy. Hum Gene Ther (2014) 0.77
Early osteoblastic differentiation induced by dexamethasone enhances adenoviral gene delivery to marrow stromal cells. J Orthop Res (2004) 0.77
Activation of refractory T cell responses against hepatitis C virus core protein by ablation of interfering hydrophobic domains. Mol Ther (2005) 0.77
Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model. Hum Gene Ther (2011) 0.76
Common cold, uncommon variation. N Engl J Med (2009) 0.75
Bone regeneration through transplantation of genetically modified cells. Clin Plast Surg (2003) 0.75
Evaluation of noncontact mapping by comparison with simultaneous multisite contact recordings in acute ischemic ventricular fibrillation. J Cardiovasc Electrophysiol (2010) 0.75
Transcatheter non-contact microwave ablation may enable circumferential renal artery denervation while sparing the vessel intima and media. EuroIntervention (2016) 0.75
Generation of multivalent genome-wide T cell responses in HLA-A*0201 transgenic mice by an HIV-1 expression library immunization (ELI) vaccine. Res Initiat Treat Action (2003) 0.75
Revised non-contact mapping of ventricular scar in a post-infarct ovine model with validation using contact mapping and histology. Europace (2010) 0.75